Youn C. Park

6.3k total citations · 3 hit papers
20 papers, 3.1k citations indexed

About

Youn C. Park is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Youn C. Park has authored 20 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 7 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Oncology. Recurrent topics in Youn C. Park's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Sarcoma Diagnosis and Treatment (4 papers). Youn C. Park is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Sarcoma Diagnosis and Treatment (4 papers). Youn C. Park collaborates with scholars based in United States, Spain and France. Youn C. Park's co-authors include Peter De Porre, Luis Fein, Kim N., Karim Fizazi, Nobuaki Matsubara, Andrew Protheroe, Mary B. Todd, B. Yа. Alekseev, Mustafa Özgüroğlu and Dingwei Ye and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Youn C. Park

20 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

2017 1.4k citations Karim Fizazi, Luis Fein et al. New England Journal of Medicine profile →
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

2018 868 citations Matthew R. Smith, Fred Saad et al. New England Journal of Medicine profile →
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

2009 397 citations George D. Demetri, Sant P. Chawla et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Youn C. Park

Since Specialization

Citations

This map shows the geographic impact of Youn C. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youn C. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youn C. Park more than expected).

Fields of papers citing papers by Youn C. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youn C. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youn C. Park. The network helps show where Youn C. Park may publish in the future.

Co-authorship network of co-authors of Youn C. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Youn C. Park. A scholar is included among the top collaborators of Youn C. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youn C. Park. Youn C. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer breakdown → 2018 ·New England Journal of Medicine ·Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Angela Lopez‐Gitlitz, Géralyn C. Trudel, Byron M. Espina, Youyi Shu, Youn C. Park, Wayne Rackoff, Margaret K. Yu, Eric J. Small	868
2	Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. 2018 ·Journal of Clinical Oncology ·Karim Fizazi, Susan Feyerabend, Nobuaki Matsubara, Mustafa Özgüroğlu, Luis Fein, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Giri Sulur, Andrew Protheroe, Peter De Porre, Susan Li, Youn C. Park, Suneel Mundle, NamPhuong Tran, Kim N.	4
3	Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. 2018 ·Journal of Clinical Oncology ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Anders Bjartell, Luca Galli, Jae‐Lyun Lee, Danish Mazhar, Scott North, David Olmos, H. Suttmann, Qing Zou, Susan Li, Jason Martin, Youn C. Park, Giri Sulur, Kris Deprince, Peter De Porre, Kim N.	7
4	SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). 2018 ·Journal of Clinical Oncology ·Eric J. Small, Fred Saad, Simon Chowdhury, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Hiroji Uemura, Angela Lopez‐Gitlitz, (unknown), Byron M. Espina, Youyi Shu, Youn C. Park, Wayne Rackoff, Margaret K. Yu, Matthew R. Smith, (unknown)	12
5	Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial. 2018 ·Journal of Clinical Oncology ·Kim N., NamPhuong Tran, Susan Feyerabend, Nobuaki Matsubara, Mustafa Özgüroğlu, Luis Fein, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Giri Sulur, Andrew Protheroe, Peter De Porre, Susan Li, Youn C. Park, Suneel Mundle, Karim Fizazi	1
6	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer breakdown → 2017 ·New England Journal of Medicine ·Karim Fizazi, (unknown), Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N.	1413
7	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial 2017 ·Investigational New Drugs ·Emiliano Calvo, Analía Azaro, Jordi Rodón, Luc Dirix, Manon Huizing, Francis M. Senecal, Patricia LoRusso, Lorrin Yee, Italo Poggesi, Jan de Jong, Spyros Triantos, Youn C. Park, Roland E. Knoblauch, Trilok Parekh, George D. Demetri, Margaret von Mehren	2
8	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. 2017 ·Journal of Clinical Oncology ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N., (unknown)	2
9	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. 2017 ·Journal of Clinical Oncology ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N., (unknown)	9
10	Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer 2016 ·Clinical Pharmacokinetics ·Xu Steven Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, Peter De Porre, An Vermeulen, Italo Poggesi, Partha Nandy	14
11	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS). 2016 ·Journal of Clinical Oncology ·George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Anthony Elias, (unknown), Roland E. Knoblauch, Youn C. Park, George Wang, Nushmia Z. Khokhar, Robert G. Maki, Shreyaskumar Patel, Charles S. Cleeland	9
12	Trabectedin (T)-related liver toxicity: Results of a pharmacokinetic study with T in patients with hepatic dysfunction (OVC1004) and experience from a phase 3 clinical trial (SAR3007). 2016 ·Journal of Clinical Oncology ·Emiliano Calvo, Analía Azaro, Luc Dirix, Manon Huizing, Francis M. Senecal, Patricia LoRusso, Lorrin Yee, (unknown), Spyros Triantos, Youn C. Park, Roland E. Knoblauch, Trilok Parekh, George D. Demetri, (unknown)	2
13	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients 2015 ·Clinical Cancer Research ·(unknown), Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, Partha Nandy	50
14	Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis 2012 ·European Journal of Cancer ·Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye, Carolyn Krasner, Jan B. Vermorken, Franco M. Muggia, Éric Pujade-Lauraine, Youn C. Park, Trilok Parekh, Andrés Poveda	75
15	Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis 2011 ·Cancer Chemotherapy and Pharmacology ·Claudia Lebedinsky, Javier Gómez, Youn C. Park, Antonio Nieto, Arturo Soto-Matos, Trilok Parekh, Vicente Alfaro, (unknown), Pilar Lardelli, Carmen Kahatt	24
16	Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules breakdown → 2009 ·Journal of Clinical Oncology ·George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Jean‐Yves Blay, Kenneth R. Hande, Mary Lou Keohan, Brian L. Samuels, Scott M. Schuetze, Claudia Lebedinsky, Yusri Elsayed, Miguel Izquierdo, Javier Gómez‐Román, Youn C. Park, Axel Le Cesne	397
17	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy 2007 ·Breast Cancer Research and Treatment ·Stephen Johnston, Semiglazov Vf, George Manikhas, Dominique Spaëth, Gilles Romieu, David Dodwell, Andrew Wardley, Patrick Neven, (unknown), Youn C. Park, (unknown), Juan José Pérez Ruixo, Angela Howes	47
18	A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older. 2007 ·Blood ·Jean‐Luc Harousseau, Giovanni Martinelli, W Wiktor-Jędrzejczak, Joseph Brandwein, (unknown), Tamás Masszi, Gert J. Ossenkoppele, (unknown), Gernot Beutel, Youn C. Park, Peter De Porre, Angela Howes	6
19	Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome 1999 ·Critical Care Medicine ·Edward Abraham, Robert P. Baughman, Eugene C. Fletcher, Stephen O. Heard, James Lamberti, Howard Levy, (unknown), Mark J. Rumbak, Jay S. Steingrub, James C. Taylor, Youn C. Park, (unknown), J. Freitag	99
20	Liposomal prostaglandin E sub 1 in acute respiratory distress syndrome 1996 ·Critical Care Medicine ·Edward Abraham, Youn C. Park, Paul S. Covington, Steven A. Conrad, Michael Schwartz	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact